Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.233
Filter
1.
Chaos ; 30(1): 013128, 2020 Jan.
Article in English | MEDLINE | ID: mdl-32013489

ABSTRACT

Bifurcation-diagram reconstruction estimates various attractors of a system without observing all of them but only from observing several attractors with different parameter values. Therefore, the bifurcation-diagram reconstruction can be used to investigate how attractors change with the parameter values, especially for real-world engineering and physical systems for which only a limited number of attractors can be observed. Although bifurcation diagrams of various systems have been reconstructed from time-series data generated in numerical experiments, the systems that have been targeted for reconstructing bifurcation diagrams from time series measured from physical phenomena so far have only been continuous-time dynamical systems. In this paper, we reconstruct bifurcation diagrams only from time-series data generated by electronic circuits in discrete-time dynamical systems with different parameter values. The generated time-series datasets are perturbed by dynamical noise and contaminated by observational noise. To reconstruct the bifurcation diagrams only from the time-series datasets, we use an extreme learning machine as a time-series predictor because it has a good generalization property. Hereby, we expect that the bifurcation-diagram reconstruction with the extreme learning machine is robust against dynamical noise and observational noise. For quantitatively verifying the robustness, the Lyapunov exponents of the reconstructed bifurcation diagrams are compared with those of the bifurcation diagrams generated in numerical experiments and by the electronic circuits.

2.
Pharmazie ; 74(2): 120-124, 2019 02 01.
Article in English | MEDLINE | ID: mdl-30782263

ABSTRACT

Aim of the study: Here, we investigated the risk factors for decreased teicoplanin plasma trough concentrations relative to the initial dosing in critically ill patients. Patients and methods: Data obtained from 80 eligible critically ill patients who received intravenous teicoplanin were retrospectively analyzed. Risk factors for decreases in teicoplanin trough concentrations 72 h after administration of teicoplanin of more than 30% relative to predicted concentrations based on initial dosing setting were identified by logistic regression analysis. Results: Although prediction trough concentration and total dose of two days no significant differences were seen between the variation group and the non-variation group, actual trough concentration was significantly different between two groups (19.9±5.6 µg/ml vs 10.3±2.2 µg/ml, p < 0.001). In multivariate analysis, serum albumin ≤ 2.2 mg/dl (odds ratio [OR] = 3.003, 95% CI 1.072-8.408; p = 0.036) and SOFA score ≥ 9 (OR = 3.498, 95% CI 1.171-10.450; p = 0.025) were significant risk factors for decreased teicoplanin plasma trough concentrations. Conclusion: In critically ill patients, high SOFA score and low serum albumin were risk factors for decreased teicoplanin plasma trough concentration during initial dosing.


Subject(s)
Anti-Bacterial Agents/blood , Infections/blood , Infections/drug therapy , Teicoplanin/blood , Administration, Intravenous , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/administration & dosage , Critical Illness , Female , Humans , Infant , Male , Middle Aged , Retrospective Studies , Risk Factors , Teicoplanin/administration & dosage , Young Adult
3.
Pharmazie ; 73(2): 110-114, 2018 Feb 01.
Article in English | MEDLINE | ID: mdl-29442014

ABSTRACT

Combination therapy with everolimus and an aromatase inhibitor such as exemestane is an effective treatment option for advanced or recurrent breast cancer. However, the therapy is often limited because of the occurrence of severe adverse events (AEs), including oral mucositis, interstitial lung disease, diarrhea, and rash. Therefore, early management of AEs is extremely important to obtain maximum treatment outcome. We investigated here the effects of comprehensive pharmaceutical care for prevention of severe AEs on patient's quality-of-life (QOL) and continuation of therapy. QOL was assessed every month based on the five-level version of EuroQol-5-Dimension (EQ-5D-5L). AEs were graded according to the Common Terminology Criteria for Adverse Events (ver 4.0). Implementation of comprehensive pharmaceutical care remarkably reduced the incidence of severe oral mucositis as compared with those without such interventions. EQ-5D-5L health states were almost constant during 6 months after intervention, ranging from 0.850 to 0.889. Median time to treatment failure (TTF) was significantly longer after intervention than before [224.0 days, 95% confidence interval (CI): 117-331 days versus 34 days, 21-47 days, hazard ratio (HR): 0.027, 95% CI: 0.005 - 0.154, p<0.001]. These findings suggest that our comprehensive pharmaceutical care is highly effective for enhancing treatment outcome by maintaining patient's QOL.


Subject(s)
Androstadienes/therapeutic use , Antineoplastic Agents/therapeutic use , Aromatase Inhibitors/therapeutic use , Breast Neoplasms/drug therapy , Everolimus/therapeutic use , Pharmaceutical Services , Adult , Aged , Androstadienes/adverse effects , Antineoplastic Agents/adverse effects , Breast Neoplasms/psychology , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Middle Aged , Patient Compliance , Postmenopause , Quality of Life , Stomatitis/chemically induced , Stomatitis/therapy , Treatment Failure
4.
Pharmazie ; 72(7): 428-432, 2017 Jul 03.
Article in English | MEDLINE | ID: mdl-29441942

ABSTRACT

Pseudomonas aeruginosa bacteremia is associated with high morbidity and mortality in critically ill patients. In this study, we assessed risk factors for clinical failure of first definitive therapy for P. aeruginosa bacteremia in critically ill patients. All patients with P. aeruginosa bacteremia who entered the intensive care unit in Gifu University Hospital from January 2006 to December 2015 were retrospectively identified from electronic records. Risk factors associated with clinical failure of the first definitive therapy for P. aeruginosa bacteremia were analyzed by logistic regression analysis. A total of 28 patients were enrolled in the analysis. On multivariate analysis, severe burns (odds ratio [OR] = 70.9, 95% CI 2.9-1720.3; p = 0.009) and SOFA score ≥ 10 (OR = 28.5, 95% CI 1.1-754.3; p = 0.045) were significant factors in the clinical failure of first definitive therapy for P. aeruginosa bacteremia. The clinical success rate of first definitive therapy was significantly reduced in patients with these risk factors compared with those without them (p < 0.001). Severe burns and a SOFA score (≥ 10) were significant risk factors associated with the clinical failure of first definitive therapy for P. aeruginosa bacteremia in critically ill patients. We therefore recommend the use of therapeutic drug monitoring to optimize antibiotic dosing in these critically ill patients.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Bacteremia/drug therapy , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/isolation & purification , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Bacteremia/microbiology , Burns/complications , Critical Illness , Drug Monitoring/methods , Female , Humans , Intensive Care Units , Logistic Models , Male , Middle Aged , Multivariate Analysis , Organ Dysfunction Scores , Pseudomonas Infections/microbiology , Retrospective Studies , Risk Factors , Treatment Failure , Young Adult
5.
Pharmazie ; 72(1): 53-57, 2017 Jan 10.
Article in English | MEDLINE | ID: mdl-29441898

ABSTRACT

AIM OF THE STUDY: A simplified chart to determine the initial loading dose of teicoplanin (TEIC chart) for achieving the target trough concentration was developed. The aim of the present study was to evaluate the usefulness of this chart in critically ill patients. PATIENTS AND METHODS: The initial loading dose and maintenance dose to achieve a target trough concentration ≥10 µg/mL on day 4 was determined using the teicoplanin TDM software and presented in a TEIC chart. The dosage of teicoplanin, including the loading dose for the first 2 days and the maintenance dose thereafter, was selected from the chart (chart method, N = 41) or calculated using TDM software (software method, N = 39). RESULTS: The performance rate of initial loading of teicoplanin increased from 83.0% to 100% after the TEIC chart was introduced (P = 0.016). The TEIC chart significantly reduced the time required for determining the initial loading dose compared with the use of software (1.9±0.6 min vs. 29.7±13.8 min, P < 0.001). No significant differences were observed in the rates of achieving a target level ≥10 µg/mL (P = 0.766). CONCLUSION: The TEIC chart enables a simple, rapid, and reliable determination of teicoplanin dosage.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/blood , Critical Illness , Teicoplanin/administration & dosage , Teicoplanin/blood , Adolescent , Adult , Aged , Aged, 80 and over , Algorithms , Anti-Bacterial Agents/therapeutic use , Female , Humans , Infections/drug therapy , Infections/microbiology , Male , Middle Aged , Predictive Value of Tests , Reproducibility of Results , Retrospective Studies , Software , Staphylococcal Infections/drug therapy , Teicoplanin/therapeutic use , Young Adult
6.
J Clin Pharm Ther ; 41(1): 19-25, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26678686

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Antimicrobial stewardship is required to ensure the appropriate use of antimicrobials. However, no reports have been published on clinical outcomes of implementation of antimicrobial stewardship in patients receiving pathogen-specific antibiotics. METHOD: To evaluate the clinical outcomes of patients who received drugs, we conducted a single-centre, retrospective study of the effects of an antimicrobial stewardship programme targeting methicillin-resistant Staphylococcus aureus (MRSA). RESULTS: The time to administer effective antimicrobials was significantly (median number of days, 3 before vs. 0 after, P < 0·001) shortened, and the rate of de-escalation was significantly elevated (47·1% vs. 96·2%, P < 0·001) after implementation of daily review. The 60-day clinical failure associated with Gram-positive bacterial infection was significantly reduced (33·3% vs. 17·6%, P = 0·007) after intervention. WHAT IS NEW AND CONCLUSIONS: Daily review of administration of antimicrobials targeting MRSA was highly effective in improving clinical outcomes by optimizing early antimicrobial therapy.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Methicillin-Resistant Staphylococcus aureus/drug effects , Staphylococcal Infections/drug therapy , Aged , Anti-Bacterial Agents/therapeutic use , Drug Utilization Review , Female , Gram-Positive Bacterial Infections/drug therapy , Humans , Male , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Middle Aged , Retrospective Studies , Staphylococcal Infections/microbiology , Time Factors , Treatment Outcome
7.
Clin Exp Immunol ; 170(1): 86-93, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22943204

ABSTRACT

We investigated the non-genomic effects of glucocorticoids (GCs) on inhibition of plasma membrane lipid raft formation in activated human basophils. Human basophils obtained from house dust mite (HDM)-sensitive volunteers were pretreated with hydrocortisone (CORT) or dexamethasone (Dex) for 30 min and then primed with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) or HDM (10 µg/ml). The expression of CD63, a basophil activation marker, was assessed by flow cytometry. Membrane-bound GC receptors (mGCRs) were analysed by flow cytometry and confocal laser microscopy. Lipid rafts were assessed using a GM1 ganglioside probe and visualization by confocal laser microscopy. Pretreatment of basophils with CORT (10(-4) M and 10(-5) M) and Dex (10(-7) M) significantly inhibited CD63 expression 20 min after addition of PMA or HDM. The inhibitory effects of GCs were not altered by the nuclear GC receptor (GCR) antagonist RU486 (10(-5) M) or the protein synthesis inhibitor cycloheximide (10(-4) M) (P < 0·05). CORT coupled to bovine serum albumin (BSA-CORT) mimicked the rapid inhibitory effects of CORT, suggesting the involvement of mGCRs. mGCRs were detectable on the plasma membrane of resting basophils and formed nanoclusters following treatment with PMA or HDM. Pretreatment of cells with BSA-CORT inhibited the expression of mGCRs and nanoclustering of ganglioside GM1 in lipid rafts. The study provides evidence that non-genomic mechanisms are involved in the rapid inhibitory effect of GCs on the formation of lipid raft nanoclusters, through binding to mGCRs on the plasma membrane of activated basophils.


Subject(s)
Basophils/drug effects , Glucocorticoids/pharmacology , Membrane Microdomains/drug effects , Pyroglyphidae/metabolism , Receptors, Glucocorticoid/metabolism , Animals , Basophils/immunology , Basophils/metabolism , Cattle , Cell Membrane/immunology , Cell Membrane/metabolism , Cells, Cultured , Cycloheximide/pharmacology , Dexamethasone/immunology , Dexamethasone/pharmacology , Flow Cytometry , G(M1) Ganglioside/metabolism , Gene Expression Regulation , Glucocorticoids/immunology , Humans , Hydrocortisone/immunology , Hydrocortisone/pharmacology , Leukocytes, Mononuclear/cytology , Membrane Microdomains/immunology , Membrane Microdomains/metabolism , Microscopy, Confocal , Mifepristone/pharmacology , Pyroglyphidae/immunology , Receptors, Glucocorticoid/analysis , Receptors, Glucocorticoid/antagonists & inhibitors , Serum Albumin, Bovine/metabolism , Tetradecanoylphorbol Acetate/immunology , Tetradecanoylphorbol Acetate/pharmacology , Tetraspanin 30/analysis , Tetraspanin 30/antagonists & inhibitors
8.
Int J Clin Pract ; 66(10): 999-1008, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22846073

ABSTRACT

BACKGROUND: Antimicrobial stewardship has not always prevailed in a wide variety of medical institutions in Japan. METHODS: The infection control team was involved in the review of individual use of antibiotics in all inpatients (6348 and 6507 patients/year during the first and second annual interventions, respectively) receiving intravenous antibiotics, according to the published guidelines, consultation with physicians before prescription of antimicrobial agents and organisation of education programme on infection control for all medical staff. The outcomes of extensive implementation of antimicrobial stewardship were evaluated from the standpoint of antimicrobial use density, treatment duration, duration of hospital stay, occurrence of antimicrobial-resistant bacteria and medical expenses. RESULTS: Prolonged use of antibiotics over 2 weeks was significantly reduced after active implementation of antimicrobial stewardship (2.9% vs. 5.2%, p < 0.001). Significant reduction in the antimicrobial consumption was observed in the second-generation cephalosporins (p = 0.03), carbapenems (p = 0.003), aminoglycosides (p < 0.001), leading to a reduction in the cost of antibiotics by 11.7%. The appearance of methicillin-resistant Staphylococcus aureus and the proportion of Serratia marcescens to Gram-negative bacteria decreased significantly from 47.6% to 39.5% (p = 0.026) and from 3.7% to 2.0% (p = 0.026), respectively. Moreover, the mean hospital stay was shortened by 2.9 days after active implementation of antimicrobial stewardship. CONCLUSION: Extensive implementation of antimicrobial stewardship led to a decrease in the inappropriate use of antibiotics, saving in medical expenses, reduction in the development of antimicrobial resistance and shortening of hospital stay.


Subject(s)
Anti-Infective Agents/therapeutic use , Cross Infection/prevention & control , Infection Control/organization & administration , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/economics , Anti-Infective Agents/economics , Cost Savings , Cross Infection/economics , Drug Resistance, Bacterial , Female , Hospitals, University , Humans , Infection Control/economics , Infection Control/methods , Infusions, Intravenous , Japan , Kaplan-Meier Estimate , Length of Stay , Male , Middle Aged , Outcome Assessment, Health Care , Professional Practice , Unnecessary Procedures
9.
Neuropathol Appl Neurobiol ; 37(7): 791-802, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21696416

ABSTRACT

AIMS: We recently demonstrated accumulation of α-synuclein aggregates of the cardiac sympathetic nerve in Parkinson's disease (PD) and a possible relationship between degeneration of the cardiac sympathetic nerve and α-synuclein aggregates. The aim of this study is to determine whether there is a difference in the degenerative process between unmyelinated and myelinated axons of the cardiac nerve. METHODS: We immunohistochemically examined cardiac tissues from four pathologically verified PD patients, nine patients with incidental Lewy body disease (ILBD) and five control subjects, using antibodies against neurofilament, myelin basic protein (MBP) and α-synuclein. First, we counted the number of neurofilament-immunoreactive axons not surrounded by MBP (unmyelinated axons) and those surrounded by MBP (myelinated axons). Next, we counted the number of unmyelinated and myelinated axons with α-synuclein aggregates. RESULTS: (i) The percentage of unmyelinated axons in PD (77.5 ± 9.14%) was significantly lower compared to that in control subjects (92.2 ± 2.40%). (ii) The ratio of unmyelinated axons with α-synuclein aggregates to total axons with α-synuclein aggregates in ILBD ranged from 94.4 to 100 (98.2 ± 2.18%). Among axons with α-synuclein aggregates, unmyelinated axons were the overwhelming majority, comprising 98.2%. CONCLUSION: These findings suggest that in PD unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve, because α-synuclein aggregates accumulate much more abundantly in unmyelinated axons.


Subject(s)
Axons/pathology , Heart/innervation , Nerve Degeneration/pathology , Nerve Fibers, Myelinated/pathology , Nerve Fibers, Unmyelinated/pathology , Parkinson Disease/pathology , Aged , Aged, 80 and over , Female , Humans , Lewy Body Disease/pathology , Male , Middle Aged
10.
Opt Express ; 19(2): 1051-6, 2011 Jan 17.
Article in English | MEDLINE | ID: mdl-21263643

ABSTRACT

We experimentally demonstrate the generation of a squeezed vacuum pulse at 810 nm with a fiber polarization interferometer. During femtosecond laser pulse propagation through an optical fiber in the normal dispersion regime, only self-phase modulation within a short length contributes to pulse squeezing since the laser pulse is immediately broadened. Guided acoustic-wave Brillouin scattering (GAWBS) noise that increases in proportional to the fiber length is also lower with shorter fibers. Consequently, a maximum noise reduction of 2.1 dB (4.8 dB when corrected for losses) is obtained using a 40-cm-long single mode optical fiber.


Subject(s)
Interferometry/instrumentation , Lasers , Optical Fibers , Refractometry/instrumentation , Equipment Design , Equipment Failure Analysis
11.
Pharmazie ; 66(3): 226-9, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21553656

ABSTRACT

The development of a single-dose extended release formulation of azithromycin (AZ-SR) improves the adherence. However, gastrointestinal side effects such as diarrhea are frequent adverse drug reactions. The aim of the present study was to investigate the incidence of patient-reported in a diarrhea and the convenience of intake of AZ-SR in an Asian population. To assess the incidence of diarrhea and convenience of intake, patient-reported in a questionnaire about the incidence, onset, duration and severity of diarrhea, shape of stool, and patients' impression on taste. The drug was prepared and used in common with the hospital pharmacy and the community pharmacy. AZ-SR was prescribed in 96 outpatients, among whom 81 patients received the medicine and the questionnaire at the hospital pharmacy or one of five neighboring community pharmacies. The recovery of the questionnaire was 40.7%. Diarrhea occurred in 18 of 33 patients (54.5%), which was more frequent than in earlier reports, although the symptom was mild (grade 1-2) and occurred in most cases within 2 days. Approximately one third of patients reported inconvenience in taking the formulation in respect of the ease (36.4%), amount (42.4%), and unpleasant bitter taste (36.4%). We report here the importance of collaboration between hospital pharmacists and community pharmacists in providing accurate drug information, including the incidence of diarrhea, to patients receiving AZ-SR.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Azithromycin/administration & dosage , Azithromycin/adverse effects , Diarrhea/chemically induced , Diarrhea/epidemiology , Aged , Chemistry, Pharmaceutical , Community Pharmacy Services , Data Collection , Delayed-Action Preparations , Female , Humans , Japan/epidemiology , Male , Middle Aged , Patient Satisfaction , Pharmacy Service, Hospital , Surveys and Questionnaires
12.
J Prev Alzheimers Dis ; 8(4): 495-502, 2021.
Article in English | MEDLINE | ID: mdl-34585225

ABSTRACT

BACKGROUND: PET (positron emission tomography) and CSF (cerebrospinal fluid) provide the "ATN" (Amyloid, Tau, Neurodegeneration) classification and play an essential role in early and differential diagnosis of Alzheimer's disease (AD). OBJECTIVE: Biomarkers were evaluated in a Japanese multicenter study on cognitively unimpaired subjects (CU) and early (E) and late (L) mild cognitive impairment (MCI) patients. MEASUREMENTS: A total of 38 (26 CU, 7 EMCI, 5 LMCI) subjects with the age of 65-84 were enrolled. Amyloid-PET and FDG-PET as well as structural MRI were acquired on all of them, with an additional tau-PET with 18F-flortaucipir on 15 and CSF measurement of Aß1-42, P-tau, and T-tau on 18 subjects. Positivity of amyloid and tau was determined based on the positive result of either PET or CSF. RESULTS: The amyloid positivity was 13/38, with discordance between PET and CSF in 6/18. Cortical tau deposition quantified with PET was significantly correlated with CSF P-tau, in spite of discordance in the binary positivity between visual PET interpretation and CSF P-tau in 5/8 (PET-/CSF+). Tau was positive in 7/9 amyloid positive and 8/16 amyloid negative subjects who underwent tau measurement, respectively. Overall, a large number of subjects presented quantitative measures and/or visual read that are close to the borderline of binary positivity, which caused, at least partly, the discordance between PET and CSF in amyloid and/or tau. Nine subjects presented either tau or FDG-PET positive while amyloid was negative, suggesting the possibility of non-AD disorders. CONCLUSION: Positivity rate of amyloid and tau, together with their relationship, was consistent with previous reports. Multicenter study on subjects with very mild or no cognitive impairment may need refining the positivity criteria and cutoff level as well as strict quality control of the measurements.


Subject(s)
Alzheimer Disease , Biomarkers/cerebrospinal fluid , Cognitive Dysfunction/diagnosis , Positron-Emission Tomography , Prodromal Symptoms , Aged , Aged, 80 and over , Amyloid beta-Peptides/cerebrospinal fluid , Amyloid beta-Peptides/metabolism , Carbolines , Cognitive Dysfunction/cerebrospinal fluid , Humans , Japan , Magnetic Resonance Imaging , tau Proteins/cerebrospinal fluid , tau Proteins/metabolism
13.
J Exp Med ; 186(5): 757-66, 1997 Aug 29.
Article in English | MEDLINE | ID: mdl-9271591

ABSTRACT

T cell receptor (TCR) recognition of peptide-major histocompatibility complex antigens can elicit a diverse array of effector activities. Here we simultaneously analyze TCR engagement and the production of multiple cytokines by individual cells in a clonal Th1 CD4(+) cell population. Low concentrations of TCR ligand elicit only interferon-gamma (IFN-gamma) production. Increasing ligand recruits more cells into the IFN-gamma+ pool, increases IFN-gamma produced per cell, and also elicits IL-2, but only from cells already making IFN-gamma. Most cells producing only IFN-gamma show less TCR downmodulation than cells producing both cytokines, consistent with a requirement for more TCR signaling to elicit IL-2 than to evoke IFN-gamma synthesis. These studies emphasize the hierarchical organization of TCR signaling thresholds for induction of distinct cytokine responses, and demonstrate that this threshold phenomenon applies to individual cells. The existence of such thresholds suggests that antigen dose may dictate not only the extent, but also the quality of an immune response, by altering the ratios of the cytokines produced by activated T cells. The quantitative relationships in this response hierarchy change in response to costimulation through CD28 or LFA-1, as well as the differentiation state of the lymphocyte, explaining how variations in these parameters in the face of a fixed antigen load can qualitatively influence immune outcomes. Finally, although the IFN-gamma/IL-2 hierarchy is seen with most cells, among cells with the greatest TCR downmodulation, some produce only IFN-gamma and not IL-2, and the amount of IFN-gamma exceeds that in double producers. Thus, these single cell analyses also provide clear evidence of nonquantitative intraclonal heterogeneity in cytokine production by long-term Th1 cells, indicating additional complexity of T cell function during immune responses.


Subject(s)
Interferon-gamma/biosynthesis , Interleukin-2/biosynthesis , Receptors, Antigen, T-Cell/metabolism , Signal Transduction , Th1 Cells/immunology , Amino Acid Sequence , Animals , Antigen Presentation , Antigens, CD/immunology , Clone Cells , Coculture Techniques , Down-Regulation , Enzyme-Linked Immunosorbent Assay , Gene Expression Regulation , Interleukin-3/biosynthesis , Ligands , Lymphocyte Activation , Major Histocompatibility Complex/immunology , Mice , Molecular Sequence Data , Peptide Fragments/chemical synthesis , Peptide Fragments/immunology , Peptide Fragments/metabolism , RNA, Messenger/metabolism , Th1 Cells/metabolism
14.
Ann Biol Clin (Paris) ; 68(1): 9-25, 2010.
Article in French | MEDLINE | ID: mdl-20146974

ABSTRACT

Urinary excretion of albumin indicates kidney damage and is recognized as a risk factor for progression of kidney disease and cardiovascular disease. The role of urinary albumin measurements has focused attention on the clinical need for accurate and clearly reported results. The National Kidney Disease Education Program and the IFCC convened a conference to assess the current state of preanalytical, analytical, and postanalytical issues affecting urine albumin measurements and to identify areas needing improvement. The chemistry of albumin in urine is incompletely understood. Current guidelines recommend the use of the albumin/creatinine ratio (ACR) as a surrogate for the erro-prone collection of timed urine samples. Although ACR results are affected by patient preparation and time of day of sample collection, neither is standardized. Considerable intermethod differences has been reported for both albumin and creatinine measurement, but trueness is unknown because there are no reference measurement procedures for albumin and no referance materials for either analyte in urine. The recommanded reference intervals for the ACR do not take into account the large intergroup differences in creatinine excretion (e.g., related to differences in age, sex, and ethicity) nor the continuous increase in risk related to albumin excretion. Clinical needs have been identified for standardization of (a) urine collection methodes, (b) urine albumin and creatinine measurements based on a complete reference system, (c) reporting of test results, and (d) reference intervals for the ACR.


Subject(s)
Albuminuria/diagnosis , Creatinine/urine , Humans , Kidney Diseases/diagnosis , Nephelometry and Turbidimetry , Reference Standards , Specimen Handling
15.
Clin Transl Oncol ; 22(6): 919-927, 2020 Jun.
Article in English | MEDLINE | ID: mdl-31576495

ABSTRACT

PURPOSE: Immune checkpoint inhibitors (ICIs) show promising clinical activity in advanced cancers. However, the safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies (ANA) are unclear. METHODS: 191 patients treated with nivolumab, pembrolizumab, atezolizumab, or durvalumab for unresectable advanced cancers between September 2014 and December 2018 were identified retrospectively. Patients were divided into positive (ANA titers ≥ 1:160) and negative ANA groups (ANA titers < 1:160). Development of immune-related adverse events (irAEs), the overall response rate (ORR), and disease control rate (DCR) were monitored. RESULTS: Positive ANA titers were seen in 9 out of 191 patients. Four patients in the positive ANA group and 69 patients in the negative group developed irAEs of any grade without a significant difference between the groups. The development of endocrine, pulmonary, and cutaneous irAEs was not significant, whereas positive ANA was significantly higher in patients who developed colitis (2/9) than in patients who did not (3/182, P = 0.0002). DCR in the positive and negative ANA group was 37.5% and 67.5%, respectively, and was not statistically significant, but had better efficacy in patients without ANA (P = 0.08). ANA-related autoimmune diseases such as SLE, Sjögren's syndrome, MCTD, scleroderma, dermatomyositis, and polymyositis was not induced in either group. However, one patient with preexisting dermatomyositis had a flare up after initiation of atezolizumab. CONCLUSION: Further studies to identify predictive factors for the development of irAEs are required to provide relevant patient care and maximize the therapeutic benefits of ICIs.


Subject(s)
Antibodies, Antinuclear/blood , Antineoplastic Agents, Immunological/therapeutic use , Immune Checkpoint Inhibitors/therapeutic use , Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , B7-H1 Antigen/antagonists & inhibitors , Drug-Related Side Effects and Adverse Reactions/blood , Drug-Related Side Effects and Adverse Reactions/pathology , Female , Humans , Male , Middle Aged , Neoplasms/blood , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Retrospective Studies , Treatment Outcome
16.
JDR Clin Trans Res ; 5(1): 50-61, 2020 01.
Article in English | MEDLINE | ID: mdl-30975019

ABSTRACT

INTRODUCTION: Many reports show that denture adhesives improve the retention and stability of dentures. However, few randomized controlled trials have examined the effects of denture adhesives. OBJECTIVE: This 10-center randomized controlled trial with parallel groups involving 200 edentulous patients wearing complete dentures aimed to evaluate the effects of short-term use of cream and powder denture adhesives. METHODS: Patients were allocated into 2 cream- and powder-type adhesive groups and 1 control group. Intervention groups were treated with the 2 adhesives (1 each), and the control group received saline solution. Adhesive or control was applied to the denture-mucosal surface for 4 d, and data at baseline and after day 4 of intervention (i.e., 8 meals) were obtained. Patient satisfaction was evaluated with a 100-mm visual analog scale. Oral health-related quality of life was measured with the Japanese version of the Oral Health Impact Profile for Edentulous Patients. Perceived chewing ability was evaluated by a questionnaire regarding ease of chewing and swallowing food. Between-group comparisons were performed with Kruskal-Wallis tests with the Mann-Whitney U test adjusted by Bonferroni correction. Within-group comparisons of pre- and postintervention measurements were performed with the Wilcoxon signed-rank test. Intention-to-treat analysis was also performed. RESULTS: Between-group comparisons showed no significant differences for general satisfaction or Oral Health Impact Profile for Edentulous Patients. However, significant differences in satisfaction with various denture functions with cream- and powder-type adhesives were seen in pre- and postintervention comparisons (P < 0.05). Significant differences were also observed for perceived chewing ability of hard foods (P < 0.05). CONCLUSION: These results suggest that although denture adhesives do not invariably improve denture function, they do affect subjective evaluations and possibly chewing of hard foods. Therefore, the effects of denture adhesive use are insufficient to resolve any fundamental dissatisfaction with dentures ( ClinicalTrials.gov NCT01712802 ). KNOWLEDGE TRANSFER STATEMENT: The results of this study suggest that denture adhesives should be applied under certain conditions; however, an appropriate diagnosis is important before application. These practice-based data provide information to establish evidence-based guidelines for applying denture adhesives.


Subject(s)
Denture Retention , Mouth, Edentulous , Dental Cements , Denture, Complete , Humans , Quality of Life
17.
Ann Oncol ; 20(9): 1483-1488, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19282468

ABSTRACT

BACKGROUND: This report describes quality of life (QoL) findings of a randomized study comparing gefitinib with docetaxel in patients with advanced/metastatic pretreated non-small-cell lung cancer. PATIENTS AND METHODS: This open-label, phase III study randomized 490 Japanese patients to gefitinib (250 mg/day) or docetaxel (60 mg/m(2)/3 weeks), with survival as the primary outcome. Preplanned QoL analyses included Functional Assessment of Cancer Therapy-Lung (FACT-L), Trial Outcome Index (TOI) and Lung Cancer Subscale (LCS) improvement rates, and mean change from baseline. RESULTS: Gefitinib showed statistically significant benefits over docetaxel in QoL improvement rates (FACT-L 23% versus 14%, P = 0.023; TOI 21% versus 9%, P = 0.002) and mean change from baseline score [mean treatment difference: FACT-L 3.72 points, 95% confidence interval (CI) 0.55-6.89, P = 0.022; TOI 4.31 points, 95% CI 2.13-6.49, P < 0.001], although differences did not meet the clinically relevant six-point change. There were no significant differences between treatments in LCS improvement rates (23% versus 20%, P = 0.562) or mean change from baseline score (0.63 points, 95% CI -0.07 to 1.34, P = 0.077). CONCLUSIONS: Gefitinib improved aspects of QoL over docetaxel, with superior objective response rate and a more favorable tolerability profile and no statistically significant difference in overall survival (although noninferiority was not statistically proven).


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Quality of Life , Quinazolines/therapeutic use , Taxoids/therapeutic use , Asian People , Docetaxel , Gefitinib , Humans , Surveys and Questionnaires , Treatment Outcome
18.
J Cell Biol ; 155(7): 1345-56, 2001 Dec 24.
Article in English | MEDLINE | ID: mdl-11756481

ABSTRACT

Membrane-type 1 matrix metalloproteinase (MT1-MMP) is an integral membrane proteinase that degrades the pericellular extracellular matrix (ECM) and is expressed in many migratory cells, including invasive cancer cells. MT1-MMP has been shown to localize at the migration edge and to promote cell migration; however, it is not clear how the enzyme is regulated during the migration process. Here, we report that MT1-MMP is internalized from the surface and that this event depends on the sequence of its cytoplasmic tail. Di-leucine (Leu571-572 and Leu578-579) and tyrosine573 residues are important for the internalization, and the mu2 subunit of adaptor protein 2, a component of clathrin-coated pits for membrane protein internalization, was found to bind to the LLY573 sequence. MT1-MMP was internalized predominantly at the adherent edge and was found to colocalize with clathrin-coated vesicles. The mutations that disturb internalization caused accumulation of the enzyme at the adherent edge, though the net proteolytic activity was not affected much. Interestingly, whereas expression of MT1-MMP enhances cell migration and invasion, the internalization-defective mutants failed to promote either activity. These data indicate that dynamic turnover of MT1-MMP at the migration edge by internalization is important for proper enzyme function during cell migration and invasion.


Subject(s)
Cell Movement/physiology , Clathrin-Coated Vesicles/physiology , Matrix Metalloproteinases/metabolism , Metallothionein/metabolism , Animals , CHO Cells , Clathrin-Coated Vesicles/ultrastructure , Cricetinae , Cytoplasm/physiology , Humans , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinases/genetics , Metallothionein/genetics , Protein Transport , Recombinant Fusion Proteins/metabolism , Recombinant Proteins/metabolism , Tissue Inhibitor of Metalloproteinase-2/metabolism , Transfection , Transferrin/metabolism
19.
J Cell Biol ; 153(5): 893-904, 2001 May 28.
Article in English | MEDLINE | ID: mdl-11381077

ABSTRACT

Migratory cells including invasive tumor cells frequently express CD44, a major receptor for hyaluronan and membrane-type 1 matrix metalloproteinase (MT1-MMP) that degrades extracellular matrix at the pericellular region. In this study, we demonstrate that MT1-MMP acts as a processing enzyme for CD44H, releasing it into the medium as a soluble 70-kD fragment. Furthermore, this processing event stimulates cell motility; however, expression of either CD44H or MT1-MMP alone did not stimulate cell motility. Coexpression of MT1-MMP and mutant CD44H lacking the MT1-MMP-processing site did not result in shedding and did not promote cell migration, suggesting that the processing of CD44H by MT1-MMP is critical in the migratory stimulation. Moreover, expression of the mutant CD44H inhibited the cell migration promoted by CD44H and MT1-MMP in a dominant-negative manner. The pancreatic tumor cell line, MIA PaCa-2, was found to shed the 70-kD CD44H fragment in a MT1-MMP-dependent manner. Expression of the mutant CD44H in the cells as well as MMP inhibitor treatment effectively inhibited the migration, suggesting that MIA PaCa-2 cells indeed use the CD44H and MT1-MMP as migratory devices. These findings revealed a novel interaction of the two molecules that have each been implicated in tumor cell migration and invasion.


Subject(s)
Cell Movement , Hyaluronan Receptors/metabolism , Leucine/analogs & derivatives , Metalloendopeptidases/metabolism , Phenylalanine/analogs & derivatives , Amino Acid Sequence , Animals , Cell Movement/drug effects , Cell Size/drug effects , Extracellular Matrix/drug effects , Extracellular Matrix/enzymology , Extracellular Matrix/metabolism , Genes, Dominant/genetics , Humans , Hyaluronan Receptors/chemistry , Hyaluronan Receptors/genetics , Leucine/pharmacology , Ligands , Matrix Metalloproteinase 14 , Matrix Metalloproteinases, Membrane-Associated , Metalloendopeptidases/antagonists & inhibitors , Metalloendopeptidases/genetics , Mice , Molecular Sequence Data , Neoplasm Invasiveness , Pancreatic Neoplasms/enzymology , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , Phenylalanine/pharmacology , Plant Proteins/pharmacology , Protein Processing, Post-Translational/drug effects , Sequence Deletion/genetics , Solubility , Sulfones/pharmacology , Thiophenes/pharmacology , Tissue Inhibitor of Metalloproteinase-1/pharmacology , Tissue Inhibitor of Metalloproteinase-2/pharmacology , Trypsin Inhibitors , Tumor Cells, Cultured , alpha-Amylases/antagonists & inhibitors
20.
J Cell Biol ; 107(3): 929-37, 1988 Sep.
Article in English | MEDLINE | ID: mdl-3047154

ABSTRACT

Immunological analysis using monoclonal antibodies against subspecies of protein kinase C revealed the predominant expression of the isozyme, type II, in human megakaryoblastic leukemic cells. We investigated the effects of phorbol diester 12-O-tetradecanoyl phorbol-13-acetate (TPA), the Ca2+ ionophore ionomycin and synthetic diacylglycerol 1-oleoyl-2-acetylglycerol (OAG) on the immunocytochemical localization of protein kinase C in these cells. Indirect immunofluorescence techniques revealed the enzyme to be located in a diffuse cytosolic pattern, in the intact cells. When the cells were exposed to 100 nM TPA, the immunofluorescent staining was translocated from the cytoplasm to the plasma membrane. The translocation was protracted and staining on the membrane decreased in parallel with the Ca2+, phospholipid-dependent protein kinase activity. Treatment of the cells with 500 nM ionomycin caused an apparent translocation comparable with that seen with TPA, however, this translocation was transient and most of the cytosolic staining was within 60 min. We also found that 30 micrograms/ml OAG did not have significant effects on distribution of the staining, but rather acted synergistically on the translocation with the suboptimal concentration of 100 nM ionomycin. A similar synergism was also observed with 10 nM TPA and 100 nM ionomycin. These results obtained in situ provide evidence that intracellular Ca2+ and diacylglycerol regulate membrane binding of the enzyme in vivo.


Subject(s)
Calcium/pharmacology , Diglycerides/pharmacology , Glycerides/pharmacology , Leukemia, Megakaryoblastic, Acute/enzymology , Protein Kinase C/analysis , Tetradecanoylphorbol Acetate/pharmacology , Anti-Bacterial Agents/pharmacology , Cell Membrane/drug effects , Cell Membrane/enzymology , Cytoplasm/enzymology , Diglycerides/chemical synthesis , Ethers/pharmacology , Fluorescent Antibody Technique , Humans , Immunoassay , Immunohistochemistry , Ionomycin , Ionophores/pharmacology , Protein Kinase C/metabolism , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL